Merck Announces Out-Licensing Agreement for Phase II-ready Ant...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
DARMSTADT, Germany, Oct.. 6, 2020 /PRNewswire-AsiaNet/-- Not intended for UK and US based media- Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® program is Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain
...
Authors: LATEST ASIANET NEWS RELEASES
